Brenig Therapeutics Unveils Superior Safety Profile Of LRRK2 Inhibitor BT-0267 With Exceptional CSF/Plasma Ratio At Future Of Parkinson's Disease Conf... menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SAN DIEGO, April 29, 2021 /PRNewswire/ i2020, an accelerator program backed by the San Diego-based venture company Torrey Pines Investment, has announced multiple start-up and follow-on investment rounds together with OrbiMed and a start-up investment in a European science-based venture, together with OrbiMed and BioGeneration Ventures (BGV). The proceeds of the follow-ons will be used to further support the three previously funded, oncology-focused companies - Lomond Therapeutics, Eil Therapeutics and Ness Therapeutics and the start-up proceeds will finance three new oncology-focused companies: Bala Therapeutics, Tegid Therapeutics, Padarn Therapeutics as well as an inflammation-focused company, Vyrnwy Therapeutics. The European science-based venture will be known as Brenig Therapeutics and will focus on neurology targets. With this additional financing, the partners continue establishing an oncology, inflammation and neurology Loch group of